Related Experiment Videos

[LH and GnRH antagonists]

F Olivennes1

  • 1Service de gynécologie obstétrique, Hôpital Antoine-Béclère, Clamart.

Insights

New gonadotropin-releasing hormone (GnRH) antagonists effectively prevent the LH surge in clinical practice. Both multiple and single-dose protocols demonstrate efficacy, with minimal impact on IVF outcomes despite minor estradiol fluctuations.

Area of Science:

  • Reproductive Endocrinology
  • In Vitro Fertilization (IVF)

Background:

  • Gonadotropin-releasing hormone (GnRH) antagonists are now clinically available.
  • These agents are crucial for preventing the premature luteinizing hormone (LH) surge during controlled ovarian stimulation.

Purpose of the Study:

  • To review the efficacy and protocols of GnRH antagonists in preventing the LH surge.
  • To assess the impact of different dosing regimens on hormonal levels and IVF outcomes.

Main Methods:

  • Description of two primary GnRH antagonist administration protocols: multiple dose regimens and a single dose protocol.
  • Analysis of studies confirming the efficacy of these antagonists in preventing the LH surge.

Main Results:

  • Multiple dose regimens (0.25 mg daily from day 5/6) maintain sufficient endogenous LH levels.
  • A single dose protocol (3 mg) in the late follicular phase can cause a transient estradiol drop related to LH decrease, but without demonstrated adverse effects on IVF results.

Conclusions:

  • GnRH antagonists offer effective LH surge prevention in IVF protocols.
  • Both multiple and single-dose regimens are viable, with the single 3 mg dose showing no proven negative impact on IVF success despite transient hormonal changes.

Related Concept Videos